Therefore, the potential for DSG2 to act as a prognostic biomarker is context dependent and influenced by factors such as organ/tissue type, cancer cell location within a tissue, genetic mutations, as well as the broader tumor microenvironment. This evidence concerns the gene DSG2 and neoplasm.